These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28600647)

  • 21. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
    Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
    J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
    Schmitz AMT; Teixeira SC; Pengel KE; Loo CE; Vogel WV; Wesseling J; Rutgers EJT; Valdés Olmos RA; Sonke GS; Rodenhuis S; Vrancken Peeters MJTFD; Gilhuijs KGA
    PLoS One; 2017; 12(5):e0176782. PubMed ID: 28531188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing
    Kirchner J; Grueneisen J; Martin O; Oehmigen M; Quick HH; Bittner AK; Hoffmann O; Ingenwerth M; Catalano OA; Heusch P; Buchbender C; Forsting M; Antoch G; Herrmann K; Umutlu L
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2328-2337. PubMed ID: 30056547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of FDG PET/CT for the Optimization of the Management of Additional Lesions Detected on Local Staging Breast MRI.
    Jalaguier-Coudray A; Delarbre B; Brenot-Rossi I; Houvenaeghel G; Villard-Mahjoub R; Viens P; Thomassin-Naggara I
    AJR Am J Roentgenol; 2016 Apr; 206(4):891-900. PubMed ID: 27003055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT.
    An YY; Kim SH; Kang BJ; Lee AW
    J Korean Med Sci; 2015 Jun; 30(6):808-15. PubMed ID: 26028936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of retrospective image fusion of ¹⁸F-FDG PET and MRI for preoperative staging of head and neck cancer: comparison with PET/CT and contrast-enhanced neck MRI.
    Kanda T; Kitajima K; Suenaga Y; Konishi J; Sasaki R; Morimoto K; Saito M; Otsuki N; Nibu K; Sugimura K
    Eur J Radiol; 2013 Nov; 82(11):2005-10. PubMed ID: 23891295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
    Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
    Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
    Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PET/MRI of the breast.
    Plecha DM; Faulhaber P
    Eur J Radiol; 2017 Sep; 94():A26-A34. PubMed ID: 28549570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer.
    Teixeira SC; Koolen BB; Vogel WV; Wesseling J; Stokkel MP; Vrancken Peeters MJ; van der Noort V; Rutgers EJ; Valdés Olmos RA
    Clin Nucl Med; 2016 Apr; 41(4):e181-6. PubMed ID: 26704731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.